Overweight and Obesity Clinical Trial
Official title:
The Effects of Exogenous Ketone Supplementation on Cardiovascular Function and Glucose Control
Verified date | April 2021 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Post-prandial hyperglycemic excursions induce a cascade of deleterious effects on the body, including increased inflammation, production of reactive oxygen species, and impaired cardiovascular function. Ingestion of an exogenous oral ketone supplement blunts hyperglycemia in response to an oral glucose tolerance test. Accordingly, it is hypothesized that exogenous ketone supplement ingestion prior to a meal could be an effective strategy for blunting postprandial hyperglycemia. Therefore, the purpose of this study is to investigate the effect of short-term (14-days) pre-meal exogenous ketone supplementation on glucose control, cardiovascular function, inflammation, and oxidative stress in individuals at an elevated risk of type 2 diabetes.
Status | Completed |
Enrollment | 15 |
Est. completion date | December 31, 2020 |
Est. primary completion date | March 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 69 Years |
Eligibility | Inclusion Criteria: - Elevated waist circumference (>102 cm for males, >88 cm for females) and/or Obesity (BMI > 30 kg/m2) and/or Diagnoses of prediabetes based on A1C (5.7-6.4%) and/or fasting plasma glucose (5.6-6.9 mmol/l) using ADA criteria Exclusion Criteria: - Competitively trained endurance athlete - Actively attempting to lose weight - History of mental illness or existing neurological disease(s) - Previous cardiovascular events (i.e., heart attack, stroke) - Diagnoses of diabetes - Hypoglycemia - Irritable bowel syndrome or inflammatory bowel disease - Taking medication that may interfere with insulin sensitivity - Currently following a ketogenic diet or taking ketone supplements - Unable to commit for 2 separate 14-day trials and unable to follow a controlled diet |
Country | Name | City | State |
---|---|---|---|
Canada | University of British Columbia, Okanagan. | Kelowna | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glucose control | Post-prandial glucose excursions will be measured by continuous glucose monitoring using the iPro2 CGM by Medtronic in both the active and placebo supplement conditions. Post-prandial glucose following breakfast, lunch, and dinner will be averaged together. | 2 hours after a meal | |
Secondary | Change from baseline flow mediated dilation at 14 days | Vascular function will be assessed by flow mediated dilation of the brachial artery using vascular ultrasound. A cuff will affixed on the forearm, distal to the brachial artery and will be inflated for 5 minutes. Flow mediation dilation will be measured over a 3-minute period following cuff release. | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline histone acetylation at 14 days | Histone H3 acetylation status will be quantified by flow cytometry using conjugated acetyl-histone H3 antibody specific for Lys9 (Pacific Blue 445) and the conjugated acetyl-histone H3 antibody specific for Lys14 (Alexa Fluor 488). | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline mitochondrial superoxide production at 14 days | Oxidative Stress will be measured by mitochondrial superoxide production in blood lymphocytes, monocytes, and neutrophils by flow cytometry using the MitoSOX red assay (ThermoFisher #M36008) and total intracellular ROS via the DCFDA assay (Sigma #D6883) | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline cognition (executive functions) at 14 days | Cognition will be assessed using a customized battery of psychometrically validated tests within the domain of executive functions using the iPad-based app BrainBaseline. The tests will be the Stroop test, task-switching test, digit-symbol substitution test, and the n-back test. | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline plasma glucose at 14 days | Venous blood samples will be taken and plasma glucose will be measured using a hexokinase method. | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline plasma insulin at 14 days | Venous blood samples will be taken and plasma insulin will be measured using a high-sensitivity human insulin ELISA. | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline plasma free fatty acids at 14 days | Venous blood samples will be taken and free fatty acids will be measured by colorimetric assay. | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline interleukin-1(IL)-1beta at 14 days | Mature IL-1beta secretion will be quantified by ELISA run in duplicate | Day 0 (Pre-intervention) and Day 14 (post-intervention) | |
Secondary | Change from baseline caspase-1 activation at 14 days | Caspase-1 activation will be quantified by flow cytometry. The fluorescent inhibitor probe FAM-YVAD-FMK binds covalently to activated caspase-1 and emits at 530nm | Day 0 (Pre-intervention) and Day 14 (post-intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03994419 -
PErioperAtive CHildhood ObesitY
|
||
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03602001 -
Attentive Eating for Weight Loss
|
N/A | |
Recruiting |
NCT06269159 -
The Power of 24-hour: Co-designing Intervention Components
|
||
Completed |
NCT03377244 -
Healthy Body Healthy Souls in the Marshallese Population
|
N/A | |
Completed |
NCT02996864 -
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
|
N/A | |
Completed |
NCT04647149 -
Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity
|
N/A | |
Terminated |
NCT03914066 -
A Group-based Treatment of Overweight and Obesity in Primary Care
|
N/A | |
Completed |
NCT03685656 -
Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers
|
N/A | |
Completed |
NCT05051579 -
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
|
Phase 2 | |
Completed |
NCT04611477 -
Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals
|
N/A | |
Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
Completed |
NCT03599115 -
Effects of Inhibitory Control Training in Eating Behaviors
|
N/A | |
Recruiting |
NCT05938894 -
Train Your Brain - Executive Function
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Recruiting |
NCT05987306 -
A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss
|
N/A | |
Completed |
NCT03792685 -
Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention
|
N/A | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Completed |
NCT04520256 -
Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy
|
Phase 2/Phase 3 | |
Completed |
NCT04979234 -
A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome
|
N/A |